Deanna Weber - Gossamer Bio Vice President of Human Resources
| GOSS Stock | USD 1.09 0.07 6.86% |
President
Ms. Deanna Weber is Vice President of Human Resources of the Company. She has over 25 years of diverse Human Resources experience in Biotechnology and Fortune 500 companies. She recently served as Human Resources Director at Celgene Corporationrationration. Before joining Celgene in 2016, Deanna served as Senior Director, Human Resources at Ambrx, Inc. from 20042016 transitioning the company from start up through acquisition. She entered the biotechnology industry in 1998 at Collateral Therapeutics. Prior to joining the biotech industry, she served at Fidelity Investments and Pacific Gas Electric. Deanna received her B.S. from California Polytechnic State University, San Luis Obispo and her MBA in Organizational Development from Westminster College.
| Professional Marks | MBA |
| Address | 3013 Science Park Road, San Diego, CA, United States, 92121 |
| Phone | 858 684 1300 |
| Web | https://www.gossamerbio.com |
Gossamer Bio Management Efficiency
The company has return on total asset (ROA) of (0.1124) % which means that it has lost $0.1124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9026) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio's management efficiency ratios could be used to measure how well Gossamer Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2025. Return On Capital Employed is likely to gain to -0.77 in 2025. At this time, Gossamer Bio's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 923.7 K in 2025, whereas Total Assets are likely to drop slightly above 293.4 M in 2025.Similar Executives
| Found 7 records | PRESIDENT Age | ||
| James Doherty | Acumen Pharmaceuticals | 57 | |
| Saraswati KenkareMitra | Alector | 57 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| Calvin Yu | Alector | 48 | |
| Fariborz Kamal | 4D Molecular Therapeutics | 63 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Sara KenkareMitra | Alector | 56 | |
Management Performance
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.11 |
Gossamer Bio Leadership Team
Elected by the shareholders, the Gossamer Bio's board of directors comprises two types of representatives: Gossamer Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gossamer. The board's role is to monitor Gossamer Bio's management team and ensure that shareholders' interests are well served. Gossamer Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gossamer Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Colin Rowlings, Senior CMC | ||
| Robert Smith, Chief Officer | ||
| Matt Cravets, Senior Biometrics | ||
| Jeff Boerneke, General Secretary | ||
| Christian Waage, Executive Vice President General Counsel | ||
| Richard MD, Chief Officer | ||
| Mario Orlando, Senior Planning | ||
| Caryn Peterson, Executive Affairs | ||
| Faheem Hasnain, Executive Chairman of the Board, Co-Founder | ||
| Laura Carter, Chief Officer | ||
| Deanna Weber, Vice President of Human Resources | ||
| Christian JD, Executive Administration | ||
| Bryan Giraudo, COO CFO | ||
| Lisa Nolan, MD Ireland |
Gossamer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gossamer Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (3.58) % | ||||
| Current Valuation | 107.73 M | ||||
| Shares Outstanding | 226.6 M | ||||
| Shares Owned By Insiders | 3.29 % | ||||
| Shares Owned By Institutions | 78.23 % | ||||
| Number Of Shares Shorted | 7.02 M | ||||
| Price To Earning | (4.61) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.